CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $4.75B, above the global median of $1.15B
- FinancialsHigh earnings quality
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.88%Below 5Y avg (0.91%)
Annual Rate
INR 32.00Paid annual
Payout Ratio
30.8%Sustainable
Last Ex-Dividend
Aug 5, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
454.74BINR4.75B · vs all stocks (USD)
Trailing P/E
40.82xRevenue (TTM)
57.76BINR603.38M · vs all stocks (USD)
Profit Margin
19.65%Beta
0.2160xvs all stocks
52-Week Change
37.95%vs all stocks
Market Capitalization
454.74BINR4.75B · vs all stocks (USD)
Enterprise Value
454.89BINR4.75B · vs all stocks (USD)
Trailing P/E
40.82xForward P/E
31.76xPEG Ratio
0.8397xPrice to Sales (TTM)
8.01xPrice to Book (MRQ)
10.22xEnterprise to Revenue
7.88xEnterprise to EBITDA
29.25xGross Margin
79.84%Profit Margin
19.65%Operating Margin
25.20%Return on Assets (TTM)
17.16%Return on Equity (TTM)
23.33%Revenue (TTM)
57.76BINR603.38M · vs all stocks (USD)
Revenue per Share (TTM)
462.34INRUpdated Aug 21, 2026Quarterly Revenue Growth
24.80%Gross Profit (TTM)
44.60BINR465.92M · vs all stocks (USD)
EBITDA (TTM)
16.74BINR174.89M · vs all stocks (USD)
Net Income (TTM)
11.35BINR118.55M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
30.90%Operating Cash Flow (TTM)
5.29BINR55.28M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
10.56BINR110.31M · vs all stocks (USD)
Trailing Annual Dividend Rate
32.00INRUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.88%vs all stocks
5-Year Average Dividend Yield
0.91%vs all stocks
Payout Ratio
30.84%Revenue
54.07BINRFY2026 · Mar 31, 2026Cost of Goods Sold
12.48BINRFY2026 · Mar 31, 2026Gross Profit
41.60BINRFY2026 · Mar 31, 2026Operating Income
13.27BINR138.58M · vs all stocks (USD)
Pre-tax Income
13.78BINRFY2026 · Mar 31, 2026Income Tax Expense
3.22BINRFY2026 · Mar 31, 2026Net Income
10.56BINRFY2026 · Mar 31, 2026EBIT
13.94BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
16.62BINRFY2026 · Mar 31, 2026Selling, General & Administrative
6.01BINRFY2026 · Mar 31, 2026Other Operating Expenses
8.03BINRFY2026 · Mar 31, 2026Non-operating Interest Income
516.00MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
161.10MINRFY2026 · Mar 31, 2026EPS (Basic)
84.53INRFY2026 · Mar 31, 2026EPS (Diluted)
84.51INRFY2026 · Mar 31, 2026Basic Shares Outstanding
124.93MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
124.93MSharesFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
5.63BINRFY2026 · Mar 31, 2026Free Cash Flow
5.57BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
1.07BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
13.78BINRFY2026 · Mar 31, 2026Stock-based Compensation
15.30MINRFY2026 · Mar 31, 2026Other Non-cash Items
-358.20MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-7.50BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-309.50MINRFY2026 · Mar 31, 2026Capital Expenditures
54.10MINRFY2026 · Mar 31, 2026Net Acquisitions
-32.60MINRFY2026 · Mar 31, 2026Purchase of Investments
-26.60BINRFY2026 · Mar 31, 2026Sale of Investments
25.49BINRFY2026 · Mar 31, 2026Other Investing Activity
453.70MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-637.60MINRFY2026 · Mar 31, 2026Common Stock Repurchase
0.00INRFY2026 · Mar 31, 2026Common Dividends Paid
-3.50BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-3.50BINRFY2026 · Mar 31, 2026Shares Outstanding
124.94MSharesUpdated Aug 21, 2026Float Shares
42.02MSharesUpdated Aug 21, 2026% Held by Insiders
63.58%vs all stocks
% Held by Institutions
24.50%vs all stocks
Total Cash (MRQ)
6.63BINR69.27M · vs all stocks (USD)
Total Cash per Share (MRQ)
53.08INRUpdated Aug 21, 2026Total Debt (MRQ)
2.66BINR27.78M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0587xCurrent Ratio (MRQ)
2.64xBook Value per Share (MRQ)
362.35INRUpdated Aug 21, 2026Total Assets
61.55BINR642.93M · vs all stocks (USD)
Total Current Assets
37.35BINRFY2026 · Mar 31, 2026Total Liabilities
16.28BINRFY2026 · Mar 31, 2026Total Non-current Assets
24.19BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
2.12BINRFY2026 · Mar 31, 2026Total Current Liabilities
14.16BINRFY2026 · Mar 31, 2026Cash
1.03BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
1.03BINRFY2026 · Mar 31, 2026Other Short-term Investments
5.60BINRFY2026 · Mar 31, 2026Accounts Receivable
18.54BINRFY2026 · Mar 31, 2026Inventory
9.39BINRFY2026 · Mar 31, 2026Accounts Payable
5.44BINRFY2026 · Mar 31, 2026Short-term Debt
2.21BINRFY2026 · Mar 31, 2026Other Current Liabilities
1.19BINRFY2026 · Mar 31, 2026Long-term Debt
394.20MINRFY2026 · Mar 31, 2026Other Non-current Liabilities
16.70MINRFY2026 · Mar 31, 2026Common Stock (Book)
250.70MINRFY2026 · Mar 31, 2026Retained Earnings
43.78BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
45.27BINR472.90M · vs all stocks (USD)
52-Week Low
2.33KINRUpdated Aug 21, 202652-Week High
3.80KINRUpdated Aug 21, 202652-Week Change
37.95%vs all stocks
Beta
0.2160xvs all stocks
50-Day MA
3.34KINRUpdated Aug 21, 2026200-Day MA
2.95KINRUpdated Aug 21, 2026Avg 10-Day Volume
82.00KSharesUpdated Aug 21, 2026Avg 30-Day Volume
102.64KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
90.72INRUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 118,549,559.452Operating Cash Flow (USD, TTM): 55,279,187.4
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.62
High structural barrier to entryNotable
Barrier to Entry: 0.50
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $4.75B, above the global median of $1.15BNotable
Market cap (USD): 4,750,221,252.765Global Median: 1,146,734,693.424
Revenue is $603.38M, above the global median of $520.53MNotable
Revenue (USD): 603,378,737.922Global Median: 520,528,949.311
Levered free cash flow is $110.31M, above the global median of $16.24MNotable
Levered free cash flow (USD): 110,309,760Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crispr Therapeutics AG
Tier 1ProductionApproval-Gated PipelineRule
Veradermics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tango Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Mgi Tech Co Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sk Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dong-E-E-JiaoCo Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
SJS Enterprises Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income GrowthThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
J.B. Chemicals & Pharmaceuticals Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income GrowthThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Thyrocare Technologies Ltd.
3 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income GrowthThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA